Endocrine Effects of Long-Term Calcineurin Inhibitor Use in Solid Organ Transplant Recipients

The study examines the endocrine effects of long-term calcineurin inhibitor (CNI) use, specifically tacrolimus and ciclosporin, in solid organ transplant recipients. Tacrolimus is more diabetogenic than ciclosporin, often leading to post-transplant diabetes mellitus, while both drugs contribute to dyslipidemia, weight gain, and bone loss. Tacrolimus can cause alopecia, whereas ciclosporin is linked to hypertrichosis. The research underscores the importance of regular monitoring and management of these side effects to improve patient outcomes. It suggests therapeutic strategies like magnesium repletion and CNI dose minimization and calls for prospective studies to validate monitoring algorithms. The document emphasizes balancing immunosuppressive therapy with managing potential side effects to prioritize allograft and patient survival.